Here's a deeper look at the headlines and their implications for our investment theses in these two health-care companies.
The Club's take: The first-of-their-kind FDA and CMS actions came in generally as anticipated, and represent incremental positives for Eli Lilly.
That's why some of the decline seen Friday in Eli Lilly shares – down over 2%, to around $453 each – could simply represent a sell-the-news situation.
Eli Lilly has said donanemab could be approved by the FDA late this year or in early 2024.
Our expectations around donanemab sales also are measured, and the drug is not the primary driver of our multiyear optimism for Eli Lilly.
Persons:
Eli Lilly, Eli Lilly's donanemab, Leqembi —, Biogen, —, Lilly's, That's, Donanemab, Lilly, donanemab, that's, Lisa Gill, UnitedHealth, Humana, Gill, What's, We'll, Jim Cramer's, Jim Cramer, Jim
Organizations:
Club, Drug Administration, Medicare, Medicaid Services, FDA, GE Healthcare, Humana, JPMorgan, CNBC
Locations:
Massachusetts